Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Wiskott-Aldrich Syndrome

Blood & Immune

Wiskott-Aldrich Syndrome (WAS) Clinical Trials

Also called WAS, X-linked thrombocytopenia, immune dysregulation

Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive immunodeficiency caused by mutations in the WAS gene encoding the WASp protein, critical for immune cell cytoskeleton function and actin polymerization. Pathophysiology involves impaired T-cell and B-cell function, defective regulatory T cell development, and abnormal immune response regulation.

In plain words, Wiskott-Aldrich syndrome is an inherited immune disorder where a gene change keeps immune cells from working properly. People with it have too few platelets, the cells that help blood clot, along with eczema and frequent infections.

Get an email when new Wiskott-Aldrich Syndrome trials open or the FDA decides. Get alerts

Wiskott-Aldrich Syndrome

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Waskyra · Immune globulin

Wiskott-Aldrich Syndrome has 2 FDA-approved medicines, 0 open or active clinical trials (0 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

More about Wiskott-Aldrich Syndrome

The classic triad includes microthrombocytopenia (platelets that are both too few and unusually small; about half of patients have counts under 20,000/µL at diagnosis), eczema with severe pruritus, and recurrent infections from bacterial, viral, and opportunistic organisms.

Keep reading about Wiskott-Aldrich Syndrome

Patients develop progressive T-cell immunodeficiency with diminished T-cell numbers and function, combined B-cell dysfunction, and impaired mucosal immunity. Progressive features include autoimmune manifestations (autoimmune hemolytic anemia, vasculitis, arthritis, inflammatory bowel disease) reported in 26-72% of patients across studies, including 72% of 55 patients in a French series (Dupuis-Girod et al., Pediatrics 2003).

Cancer, most often B-cell lymphoma, developed in 13% of patients (21 of 154) in a US survey (Sullivan et al., J Pediatr 1994, as summarized by Hosahalli Vasanna et al., 2021), and people with WAS who have autoimmune problems face a higher risk. Diagnosis combines clinical features, flow cytometry showing small platelet size and reduced/absent WASp protein in lymphocytes, and genetic testing identifying WAS gene mutations. Without a transplant or gene therapy, classic WAS shortens life. In an older National Institutes of Health series, patients who had neither a transplant nor spleen removal had a median survival of less than 5 years (Mullen et al., Blood 1993), and the median survival of all 55 patients in a French series was 14.5 years (Dupuis-Girod et al., Pediatrics 2003).

What are the symptoms of Wiskott-Aldrich Syndrome?

These are common symptoms of Wiskott-Aldrich Syndrome, and how strong they are varies from person to person.

  • Severe thrombocytopenia with petechiae and bleeding
  • Eczema with pruritus
  • Recurrent infections (bacterial, viral, fungal)
  • Autoimmune manifestations
  • Significantly increased malignancy risk
  • Lymphopenia and abnormal T-cell function

Who gets Wiskott-Aldrich Syndrome?

Exclusively males due to X-linked inheritance affecting essentially all hemizygous males, though rare manifesting heterozygous females with extreme lyonization reported. Manifests in infancy with bleeding tendency evident from newborn period and infections developing within first months of life.

Median age at diagnosis has ranged from under 2 months to 24 months across studies (Hosahalli Vasanna et al., 2021). Affects all ethnic and racial groups with estimated incidence of 1 to 10 per million males (MedlinePlus Genetics). Female carriers typically asymptomatic but can transmit disease to male offspring. No geographic variation in incidence. Not associated with familial clustering except through carrier female relatives.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Wiskott-Aldrich Syndrome?

There are currently 2 FDA-approved medications for Wiskott-Aldrich Syndrome.

etuvetidigene autotemcel
Fondazione Telethon ETS (US commercialization by Orphan Therapies)
Search
Immune globulin
immune globulin (human)

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Wiskott-Aldrich Syndrome treatment

Charity funds and drugmaker programs for Wiskott-Aldrich Syndrome, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · The Assistance Fund
    Primary Immunodeficiency fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 17, 2026.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Wiskott-Aldrich Syndrome

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Wiskott-Aldrich Syndrome resources

Reputable organizations and medical references for learning more about Wiskott-Aldrich Syndrome, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Wiskott-Aldrich Syndrome

This Wiskott-Aldrich Syndrome clinical trial finder lists studies as they become available, with eligibility criteria in plain English. Every trial comes from ClinicalTrials.gov.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

No active clinical trials yet

Wiskott-Aldrich Syndrome is a classified rare disease, but clinical trial activity for it is limited. That's part of why we track it. When a trial opens, Trial Friend will have it.

Get an email the moment a Wiskott-Aldrich Syndrome trial is registered on ClinicalTrials.gov.

Wiskott-Aldrich Syndrome patient communities

Facebook groups, Reddit communities and YouTube channels where Wiskott-Aldrich Syndrome patients, caregivers and advocacy groups talk.

Questions people ask about Wiskott-Aldrich Syndrome